netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Please also refer to the Cancer Drugs Fund list
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
 note  Use in accordance with local guidelines
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide to top
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer    
Cabozantinib tablets

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved for previously treated advanced renal cell carcinoma as per NICE TA463

Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma    
Crizotinib caps

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer    
Dasatinib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia    
Everolimus tabs (breast cancer and renal cancer)

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved as per NICE TA guidance (see links below)

Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment    
Everolimus tabs (neuroendocrine tumours)

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved for use in neuroendocrine tumours as per NICE TA449

Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease    
Gefitinib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer    
Nilotinib caps

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia    
Nintedanib caps (Vargatef)

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer    
Osimertinib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Cancer Drugs Fund
Red

Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer    
Pazopanib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma    
Sorafenib tablets

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved as per NICE Technology Appraisal guidance

Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma    
Sunitinib caps (neuroendocrine tumours)

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved for use in neuroendocrine tumours as per NICE TA449

Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease    
Sunitinib caps (renal cell, and gastrointestinal stromal tumours)

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved for use in renal cell and gastrointestinal stromal tumours as per NICE TA169 and NICE TA179

Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours    
Vemurafenib tabs

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma    
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin to top
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes First Choice Item First Choice item
Section Title Section Title (top level) Non Formulary Item Non Formulary section
Section Title Section Title (sub level)
Cytotoxic Drug
Cytotoxic Drug
Restricted Drug
Restricted Drug
CD
Controlled Drug
Unlicensed Drug
Unlicensed
High Cost Medicine
High Cost Medicine
click to search medicines.org.uk
Link to SPCs
click to search medicines.org.uk
Link to adult BNF
Track Changes
Display tracking information
click to search medicines.org.uk
Cancer Drugs Fund
Cancer Drugs Fund
   

 

Traffic Light Status Information

Status Description
  Red   Specialist Prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   
  Amber 1   Treatment can be initiated in primary care after a recommendation from an appropriate specialist  
  Amber 2   Specialist initiation followed by maintenance prescribing in primary care  
  Amber 3   Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  
  Green   Specialist and non-specialist initiation  
  Grey   Not recommended for prescribing  

netFormulary